Organisation paid for research Program year 2025 Source: CMS Open Payments

Albany Medical Center

Neither a doctor nor a teaching hospital

Research payments

$2,375,621

226 payments

Through program year 2025, Albany Medical Center is reported as receiving $2,375,621 in research payments, across 226 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $76,936 12
2024 Research $273,020 22
2023 Research $460,973 35
2022 Research $733,894 75
2021 Research $385,483 31
2020 Research $306,051 26
2019 Research $139,263 25

Breakdown

Who paid Research payments · program years 2019–2025
  1. Boston Scientific Corporation $1,246,360 77 payments
  2. Jazz Pharmaceuticals Inc. $343,886 5 payments
  3. Genentech, Inc. $267,088 39 payments
  4. Biogen, Inc. $200,616 2 payments
  5. Vertex Pharmaceuticals Incorporated $116,829 6 payments
  6. Eisai Inc. $69,727 42 payments
  7. Saluda Medical Americas, Inc. $33,322 22 payments
  8. Roche Molecular Systems, Inc. $20,900 6 payments
  9. Atricure, Inc. $16,663 6 payments
  10. Edwards Lifesciences Corporation $16,293 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. Acurate Ide $1,214,829 69 payments
  2. Phase II Study of Anti Tau in Prodromal to Mild Ad $267,088 39 payments
  3. A Phase 3 Randomized Trial for Patients With de Novo Aml Comparing Standard Therapy Including Gemtuzumab Ozogamicin Go to Cpx351 With Go $162,450 1 payment
  4. A Study to Compare Standard Chemotherapy to Therapy With Cpx-351 And/Or Gilteritinib for Patients With Newly Diagnosed Aml With Or Without Flt3 Mutations $152,436 1 payment
  5. A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 $139,606 1 payment
  6. A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $69,727 42 payments
  7. Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) $64,719 2 payments
  8. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $61,010 1 payment
  9. A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Lumbosacral Radiculopathy $45,532 2 payments
  10. ECAP Study $33,322 22 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record